Skip to main content
SpringerPlus

Table 2 Tumor response to treatment

From: Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone

 

Mitoxantrone (n=187)*

CMFP (n=178)*

All patients (n=365)*

Objective response

n

%

n

%

N

%

Complete response

4

2

9

5

13

3

Partial response

43

22

61

31

104

27

Stable disease

77

39

78

40

155

40

Progressive disease

63

32

30

15

93

24

Unknown response

10

5

16

8

26

7

Response rate (of evaluable)

47

25.1%

70

39.3%

117

32.1%

  1. * The total number of patients evaluable for response was 365 (CMFP 178, mitoxantrone 187).
  2. CMFP, combination therapy with cyclophosphamide, methotrexate, 5-fluorouracil and prednisone.
Back to article page